A French national survey on the use of antibiotic prophylaxis in cirrhotic patients

Liver International

Volumn 33, Issue 3, 2013, Pages 389-397

  Thevenot, Thierry ^a   Degand, Thibault ^a   Grelat, Natacha ^a   Elkrief, Laure ^b   Christol, Camille ^c   Moreau, Richard ^b   Henrion, Jean ^d   Cadranel, Jean François ^e   Sheppard, Frances ^f   Bureau, Christophe ^c   di Martino, Vincent ^a   Pauwels, Arnaud ^g  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b BEAUJON HOSPITAL   (France)

^c CHU PURPAN   (France)

^d Hospital de Jolimont   (Belgium)

^e CENTRE HOSPITALIER LAENNEC   (France)

^f HÔPITAL SAINT JACQUES   (France)

^g CENTRE HOSPITALIER DE GONESSE   (France)

Author keywords

Antibiotic prophylaxis; Cirrhosis; Gastrointestinal bleeding; Spontaneous bacterial peritonitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CROSS-SECTIONAL STUDY; DRUG HYPERSENSITIVITY; ENTEROCOCCAL INFECTION; ESOPHAGUS CANDIDIASIS; FEMALE; FRANCE; HEALTH CARE SURVEY; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PHYSICIAN; PRESCRIPTION; PRIMARY PREVENTION; PSEUDOMEMBRANOUS COLITIS; QUESTIONNAIRE; RECURRENT DISEASE; SECONDARY PREVENTION; SEIZURE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; SURVIVAL RATE; TENDINITIS; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FRANCE; GASTROINTESTINAL HEMORRHAGE; GUIDELINE ADHERENCE; HUMANS; LIVER CIRRHOSIS; PERITONITIS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES;

EID: 84873750841     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12093     Document Type: Article

References (31)

1. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-33.
2. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56.
3. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
4. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
5. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
6. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
7. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-9.
8. Ginés P, Angeli P, Lenz K, et al. European association for the study of the liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
9. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl. 1): S1-12.
10. Bernard B, Grangé JD, Nguyen-Khac E, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
11. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
12. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
13. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023-9.
14. Thevenot T, Cadranel JF, Di Martino V, et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology 2007; 45: 377-83.
15. Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.
16. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39: 746-53.
17. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34: 509-18.
18. Consensus conference. Complications of portal hypertension in adults: consensus text. Gastroenterol Clin Biol 2004; 28: 135-52.
19. Charpignon C, Oberti F, Bernard P, et al. Management practices for gastrointestinal hemorrhage related to portal hypertension in cirrhotic patients: evaluation of the impact of the Paris consensus workshop. Gastroenterol Clin Biol 2007; 31: 970-4.
20. Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12(4 Pt 1): 716-24.
21. Terg R, Llano K, Cobas SM, et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol 1998; 29: 437-42.
22. Gould IM, MacKenzie FM. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. J Appl Microbiol 2002; 92(Suppl.): 78S-84S.
23. Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
24. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-70.
25. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48: 774-9.
26. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104: 993-1001.
27. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 487-93.
28. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61: 297-310.
29. Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology 2012; 140: 70-7.
30. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol 2012; 5: 23-30.
31. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol 2011; 17: 2890-6.